This is a $2,709,458.08 cost-plus-fixed-fee federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Chromologic LLC, a minority-owned small business, to develop second-generation probiotics as radiation mitigators. The contract is not set aside.
The contract stems from a prior NIAID Broad Agency Announcement seeking proposals for medical countermeasures, including radiation/nuclear medical countermeasures. Chromologic's proposal was selected to advance the development of probiotic-based therapeutics to mitigate radiation-induced intestinal damage, an area of critical need for both nuclear incidents and cancer radiotherapy. This contract award builds on Chromologic's expertise in areas like biomedical engineering, molecular biology, and advanced materials, as well as its track record of securing SBIR/STTR grants and prime contracts from various federal agencies for innovative research and development projects.
Generated 3/12/25, 9:46 AM